Correction
After the publication of this article [1], we noticed that in Fig. 2, the survival curve images (C and D, lower panel) were incorrect. The corrected Fig. 2 is presented below. The correction does not affect in any our results and conclusions.
Survival curves. a Disease-free survival (DFS). b Overall survival (OS). c DFS stratified by estrogen receptor (ER) status. d OS stratified by ER status. The tentative cutoff value of 1.48 separates tumors with higher 18F-fluoromisonidazole tissue-to-blood ratio (TBR high) from those with lower 18F-fluoromisonidazole tissue-to-blood ratio (TBR low)
Reference
Asano A, Ueda S, Kuji I, Yamane T, Takeuchi H, Hirokawa E, Sugitani I, Shimada H, Hasebe T, Osaki A, et al. Intracellular hypoxia measured by (18)F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer. Breast Cancer Res. 2018;20(1):78.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Asano, A., Ueda, S., Kuji, I. et al. Correction to: Intracellular hypoxia measured by F-18 fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen-receptor positive breast (BRCR-D17-00693). Breast Cancer Res 20, 107 (2018). https://doi.org/10.1186/s13058-018-1038-3
Published:
DOI: https://doi.org/10.1186/s13058-018-1038-3